Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence - PubMed
4 hours ago
- #GLP-1
- #cardiometabolic
- #tirzepatide
- Tirzepatide is a once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
- It shows large, dose-dependent reductions in HbA1c and substantial weight loss in type 2 diabetes.
- In obesity, tirzepatide leads to marked weight reduction with improvements in waist circumference, blood pressure, triglycerides, and inflammatory biomarkers.
- It demonstrates favorable effects on lipids, ambulatory blood pressure, inflammatory markers, and kidney-related endpoints.
- Tirzepatide improves obstructive sleep apnea severity in adults with obesity.
- For cardiovascular outcomes, it shows noninferiority versus dulaglutide for major adverse cardiovascular events in type 2 diabetes with ASCVD.
- In obesity-related HFpEF, it reduces worsening heart failure events and improves health status.
- It is emerging as a key option for integrated cardiometabolic risk reduction.